DrugPatentWatch Database Preview
Biologic Drugs With Physiological Effect: Increased T Lymphocyte Activation
» See Plans and Pricing
Biologic Drugs With Physiological Effect: Increased T Lymphocyte Activation
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | OP NANO CO., LTD. (Taipei, TW) TRENDMED CO., LTD. (Beitou Dist., Taipei, TW) | 2039-02-26 | RX | Orphan | search |
Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) | 2034-04-05 | RX | Orphan | search |
Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | University of Georgia Research Foundation, Inc. (Athens, GA) | 2039-02-26 | RX | Orphan | search |
Bristol Myers Squibb | YERVOY | ipilimumab | INJECTABLE; INJECTION | 125377 | 001 | 2011-03-25 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2032-08-30 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |